Dr. Thorsten Kirschberg, Ph.D.
Senior Director, Medicinal Chemistry


Dr. Kirschberg joined Terns Pharmaceuticals with nearly two decades of experience in small molecule drug discovery. He is a co-inventor and key contributor of the approved drugs Ledipasvir®, a component of Harvoni®; a leading HCV treatment. At Gilead Sciences, Dr. Kirschberg worked on diverse projects in the therapeutic areas of virology, inflammation, and oncology. He held leadership roles involved with early lead finding to clinical candidate optimization. Dr. Kirschberg started his career at CellGate Inc., where he enabled prodrug strategies for the clinical application of cell penetrating peptides.

Dr. Kirschberg received his Ph.D. in chemistry from the University of Münster, Germany. He completed post-doctoral studies at Osaka University and Stanford University. He also holds a MBA degree from Golden Gate University.